deltatrials
Completed NA NCT00002304

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

A Randomized Comparative Multicenter Trial of Fluconazole and Ketoconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients

Sponsor: Pfizer

Conditions Candidiasis, Esophageal HIV Infections
Interventions Fluconazole Ketoconazole
Updated 6 times since 2017 Last updated: Jun 23, 2005

This NA trial investigates Candidiasis, Esophageal and HIV Infections and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed NA

  2. Sep 2024 — Sep 2025 [monthly]

    Completed NA

  3. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  4. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  5. Jun 2018 — Jan 2021 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Annandale, United States, Atlanta, United States, Battle Creek, United States, Boston, United States, Brooklyn, United States, Buffalo, United States, Chattanooga, United States, Daytona Beach, United States, Decatur, United States and 29 more location s